Brief: Akoya Biosciences And Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval For KR-HT5 In China
02/05/2024 13:14
May 2 (Reuters) - Akoya Biosciences Inc AKYA.O :
* AKOYA BIOSCIENCES AND SHANGHAI KR PHARMTECH ANNOUNCE
CHINESE
REGULATORY AGENCY PREMARKET APPROVAL FOR KR-HT5 IN CHINA
Source text for Eikon: ID:nGNX3V4S03
Further company coverage: AKYA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks